What is the bismuth quadruple therapy for Helicobacter pylori infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Bismuth Quadruple Therapy for H. pylori Infection

Bismuth quadruple therapy consists of four medications taken together: a proton pump inhibitor (PPI), bismuth subsalicylate or bismuth subcitrate, tetracycline 500 mg, and metronidazole 500 mg, administered for 14 days. This regimen is one of only two therapies that can be given empirically without susceptibility testing and remains highly effective even against antibiotic-resistant strains 1.

Standard Regimen Components and Dosing

The classic bismuth quadruple therapy includes 1:

  • Bismuth subsalicylate (e.g., Pepto-Bismol®): 2 tablets or capsules four times daily, taken 30 minutes before meals
  • Tetracycline HCl: 500 mg four times daily, taken 30 minutes after meals
  • Metronidazole: 500 mg four times daily (or three times daily in some protocols), taken 30 minutes after meals
  • PPI: Twice daily, 30 minutes before meals and at bedtime
  • Duration: 14 days for optimal efficacy

Alternative Dosing Schedule

A simplified regimen uses 1:

  • Bismuth: 2 tablets/capsules four times daily before meals
  • Tetracycline: 500 mg twice daily after meals
  • Metronidazole: 500 mg four times daily after meals
  • PPI: Twice daily before morning and evening meals

PPI Selection and Dosing

The choice of PPI significantly impacts treatment success—use high-potency PPIs and avoid pantoprazole 1. Recommended options include:

  • Esomeprazole or rabeprazole 20-40 mg twice daily (preferred)
  • Omeprazole 40 mg twice daily minimum
  • Lansoprazole 45 mg twice daily
  • Avoid pantoprazole due to lower potency (40 mg pantoprazole = only 9 mg omeprazole equivalent)

Formulation Options

Three-in-One Capsule (Pylera®)

A combination capsule containing bismuth subcitrate, metronidazole, and tetracycline is available, taken as 3 capsules four times daily with meals plus a PPI 1, 2. This formulation:

  • Simplifies administration and improves adherence
  • Achieves >90% eradication rates in real-world practice
  • Is packaged for 10 days but 14-day therapy is preferred for optimal results
  • Costs vary significantly: ~€70 in Europe vs >$900-1000 in the United States

Generic Components

All medications can be prescribed separately, which may be more cost-effective in some regions 1. Generic tetracycline costs ~$660 retail in the US but can be obtained for <$100 with discount coupons.

Clinical Efficacy

Bismuth quadruple therapy maintains eradication rates >90% as first-line therapy and remains highly effective as rescue therapy 2, 3:

  • First-line treatment: 95% modified intention-to-treat (mITT) eradication 2
  • Second-line rescue: 89% mITT eradication 2
  • Third-line and beyond: 92% mITT eradication 2
  • Against multidrug-resistant strains: 87% per-protocol eradication even with dual or triple antibiotic resistance 4

The regimen's effectiveness persists through multiple treatment lines, though cure rates drop below 67% after four or more failed attempts 4.

Treatment Duration

Fourteen-day therapy is recommended over 10-day regimens 1, 3. While 10-day courses show comparable eradication rates in some studies 5, the most recent guidelines emphasize 14 days for optimal outcomes, particularly in first-line therapy 1.

Important Caveats and Pitfalls

Tetracycline Substitution

Do not substitute doxycycline for tetracycline—results are significantly inferior 1. Minocycline may serve as an alternative when tetracycline is unavailable, but this is not standard practice 3.

Compliance

Patient adherence is the single most important factor predicting treatment success 2, 6. The three-in-one capsule formulation improves compliance compared to separate medications.

Resistance Patterns

Bismuth quadruple therapy maintains high efficacy regardless of clarithromycin, metronidazole, or levofloxacin resistance 4, 3. This makes it ideal for empiric therapy when local resistance rates are unknown or high.

Clinical Indications

Bismuth quadruple therapy is recommended as 7, 1:

  1. First-line therapy in regions where clarithromycin resistance exceeds 15%
  2. Rescue therapy after failure of clarithromycin-based triple therapy
  3. Rescue therapy after failure of fluoroquinolone-based regimens
  4. First choice for patients with penicillin allergy

Safety Profile

The regimen is generally well-tolerated 2, 3:

  • Adverse events occur in 16-23% of patients
  • Most side effects are mild to moderate gastrointestinal symptoms
  • Black/discolored stools are common but benign
  • Severe adverse events leading to discontinuation occur in only 1.7-3% of cases
  • Diarrhea is more common than with other regimens

Dosing Optimization

Standard antibiotic and bismuth doses are sufficient—higher doses do not improve eradication rates 8. The optimal regimen uses:

  • Tetracycline ≥1500 mg/day
  • Metronidazole 1500 mg/day
  • Bismuth ≥480 mg/day

Increasing doses beyond these thresholds provides no additional benefit and may increase adverse events 8.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.